Moderna Inc. and OpenAI have announced an ongoing collaboration to co-innovate with a shared vision of AI’s transformative potential in the future of business and healthcare.
 
Moderna has leveraged the power of machine learning since its beginnings. This strong data foundation, along with its culture of learning, positions the company to integrate generative AI responsibly and seamlessly into its operations and capitalize on next-generation AI innovation.
 
The organizations began their collaboration in early 2023 with the launch of Moderna’s own instance of ChatGPT, called mChat, which was internally built on top of OpenAI’s API. With more than 80% internal adoption since its debut, this initial success accelerated an AI culture that led to the deployment of ChatGPT Enterprise and its enhanced capabilities such as Advanced Analytics, Image Generation and GPTs. These GPTs are now embedded across Moderna’s business functions and are purpose-built as assistants that work beside Moderna’s employees, augmenting their roles through personalized support.
 
“Just as the introduction of the personal computer in the 1980’s changed the way we work and live, AI is on a path to completely transform our everyday lives—and OpenAI is helping to lead the way. Both our companies have shared values and are research-driven organizations pushing the boundaries of technology to drive transformation,” said Stéphane Bancel, CEO of Moderna. “Moderna has an ambitious plan to launch multiple products over the next few years, and collaborations with companies like OpenAI are critical to our ability to scale and maximize our impact on patients.”
 
“Moderna is leading the way by empowering all of its employees to use AI to tackle complex problems,” said Sam Altman, CEO of OpenAI. “We look forward to continuing to collaborate with Moderna to bring a new generation of medicines to patients in need.”
 
In the few months since adopting ChatGPT Enterprise, Moderna has deployed more than 750 GPTs across the Company that help drive automation and productivity. This includes the Company’s Dose ID GPT, which uses ChatGPT Enterprise’s Advanced Data Analytics feature to further evaluate the optimal vaccine dose selected by the clinical study team. By applying standard dose selection criteria and principles, Dose ID provides a rationale, references its sources, and generates informative charts illustrating the key findings. This allows for a detailed review, led by humans and augmented with AI input, while prioritizing safety and optimizing the vaccine dose profile prior to further development in late-stage clinical trials.